Promosyon programı Kazia Therapeutics Limited
Gelişmiş program
Basit grafik
Şirket hakkında Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.| IPO date | 1999-01-06 |
|---|---|
| ISIN | US48669G1058 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | aud |
| Див.доход ао | 26.59 |
| Дивиденд ао | 4.09 |
| Сайт | https://www.kaziatherapeutics.com |
| Цена ао | 0.9903 |
| Günlük fiyat değişimi: | -7.36% (0.95) |
|---|---|
| Haftalık fiyat değişimi: | -9.82% (0.9759) |
| Aylık fiyat değişimi: | +407.85% (0.1733) |
| 3 ayda fiyat değişimi: | +43.34% (0.614) |
| Altı ayda fiyat değişimi: | +2.34% (0.86) |
| Yıllık fiyat değişimi: | +170.8% (0.325) |
| 3 yılda fiyat değişimi: | -88.33% (7.54) |
| 5 yılda fiyat değişimi: | -78.69% (4.13) |
| Yılbaşından bu yana fiyat değişimi: | +148.62% (0.354) |
|
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
|||||||||||||||||||||||||||||||||||||
| Kurumlar | Hacim | Paylaşmak, % |
|---|---|---|
| Armistice Capital, LLC | 2475555 | 10.47 |
| Platinum Investment Management Ltd | 1821887 | 7.71 |
| Morgan Stanley | 201550 | 0.85 |
| Bank of Montreal/Can/ | 140166 | 0.59 |
| HSBC Holdings PLC | 100194 | 0.42 |
| TWO SIGMA SECURITIES, LLC | 58423 | 0.25 |
| XTX Topco Ltd | 19436 | 0.08 |
| Acadian Asset Management. LLC | 18682 | 0.08 |
| Citadel Advisors Llc | 12809 | 0.05 |
| BNP Paribas Financial Markets | 12700 | 0.05 |
| Süpervizör | İş unvanı | Ödeme | Doğum yılı |
|---|---|---|---|
| Ms. Anna Sandham | Company Secretary | N/A | |
| Dr. John Edwin Friend II, M.D. | CEO, MD & Director | 731.09k | 1970 (55 yıllar) |
| Ms. Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer | 178.56k |
Adres: Australia, Sydney, Three International Towers - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.kaziatherapeutics.com
Web sitesi: https://www.kaziatherapeutics.com
